Everand Logo

Welcome to Everand!

  • STAT

    Opinion: De-intensifying treatment for early thyroid cancer

    Choosing less-intense cancer care can make doctors and patients nervous, but it's sometimes the right thing to do.
    by H. Gilbert Welch and Gerard M. Doherty Jul 25, 2018 5 minutes
    For many people with early thyroid cancer, a less-intense operation called lobectomy is as good as complete removal of the thyroid gland.

    How much thyroid gland is enough? Can you get by with half of one?

    That question is relevant to the more than 50,000 Americans diagnosed with thyroid cancer each year. As we point out in a study published Wednesday in the New England Journal of Medicine, it is also a question that doctors who treat thyroid cancer need to give more attention to, while the rest of us consider the broader questions about the appropriate intensity of treatment for early cancer.

    First, some background on thyroid cancer. Although it is a rare cause of death, autopsies often show the existence of what is called papillary thyroid cancer. In other words, this is typically a cancer you die with — not from.

    Before the mid-1990s, the incidence of thyroid cancer had been relatively stable as ultrasound, MRI, and CT scans now detect small papillary thyroid cancers that cannot be felt. Yet despite this dramatic increase in new cases, the death rate from thyroid cancer has been rock stable.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks